Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

5.8K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced viability of encapsulated probiotics using whey protein isolate-dextran conjugates: Effect of dextran molar mass.

International journal of biological macromolecules·2026
Same author

A Double-Edged Sword: A Qualitative Study of the Minority Tax in Academic Emergency Medicine Faculty.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2025
Same author

Treatment success rate and time to culture conversion under a prospective BPaL cohort study.

IJTLD open·2025
Same author

Factors influencing initial implementation of an online community-based exercise intervention with adults living with HIV: a systems approach.

Frontiers in rehabilitation sciences·2023
Same author

Personalized Medicine in Infant Population with Cancer: Pharmacogenetic Pilot Study of Polymorphisms Related to Toxicity and Response to Chemotherapy.

Cancers·2023
Same author

Regulation of CO<sub>2</sub> by the sea in areas around Latin America in a context of climate change.

Environmental monitoring and assessment·2023

Related Experiment Video

Updated: Jan 4, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.0K

Li-Fraumeni syndrome heterogeneity.

P Gargallo1, Y Yáñez2, V Segura2

  • 1Pediatric Oncology, La Fe Hospital, Av. Fernando Abril Martorell 106, 46026, Valencia, Spain. gargallo_pabtat@gva.es.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|November 7, 2019
PubMed
Summary

Li-Fraumeni syndrome shows significant clinical variability due to TP53 gene mutations and related factors. This review explores genetic and epigenetic influences on Li-Fraumeni phenotype heterogeneity.

Keywords:
EpigenomeGenotypeLi–Fraumeni syndromePediatricsPhenotype

More Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

Related Experiment Videos

Last Updated: Jan 4, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.0K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

9.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Li-Fraumeni syndrome (LFS) is characterized by significant clinical variability, even among individuals with the same TP53 gene pathogenic variant.
  • This phenotypic heterogeneity complicates diagnosis and management of LFS.
  • The underlying causes for this wide clinical spectrum remain incompletely understood.

Purpose of the Study:

  • To review recent advances in understanding the genetic and epigenetic factors contributing to Li-Fraumeni syndrome's clinical heterogeneity.
  • To explore potential mechanisms driving the diverse phenotypes observed in LFS patients.

Main Methods:

  • Literature review of recent research on Li-Fraumeni syndrome.
  • Analysis of genetic (TP53 mutations, polymorphic variants, copy number variations) and epigenetic factors.

Main Results:

  • TP53 gene mutations are a primary cause of LFS, but variations in clinical presentation suggest additional contributing factors.
  • Polymorphic variants in TP53 or related genes, copy number variations, and epigenetic deregulation of TP53 expression are potential drivers of heterogeneity.
  • These factors can modulate the activity and impact of TP53, leading to a broad spectrum of clinical outcomes.

Conclusions:

  • Clinical variability in Li-Fraumeni syndrome is influenced by a complex interplay of genetic and epigenetic factors beyond the primary TP53 mutation.
  • Further research into these modifiers is crucial for a comprehensive understanding of LFS and for developing personalized management strategies.
  • Understanding these influences can lead to improved prediction of disease risk and tailored therapeutic approaches.